secwatch.observer — SEC 8-K summary
======================================

Issuer:     Marker Therapeutics, Inc. (MRKR)
CIK:        0001094038
Form:       8-K
Filed at:   2022-11-22T23:59:59+00:00
Accession:  0001104659-22-120986
Event type: regulatory
Sentiment:  positive
Materiality: 0.60
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

FDA clears Marker Therapeutics IND for MT-601 to treat pancreatic cancer
------------------------------------------------------------------------

- FDA cleared IND for MT-601, a six-antigen T cell therapy for locally advanced unresectable or metastatic pancreatic cancer.
- Phase 1 trial planned for 2023, combining MT-601 with front-line chemotherapy.
- New manufacturing process reduces production time from >30 days to 9 days with 90% fewer interventions.
- Interim TACTOPS study data showed multiTAA therapy plus chemo yielded better-than-expected clinical responses.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1094038/000110465922120986/0001104659-22-120986-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1094038/000110465922120986/tm2231138d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-22-120986

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer